Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report) traded up 5.6% during trading on Tuesday . The company traded as high as $3.70 and last traded at $3.7050. Approximately 870,594 shares changed hands during trading, an increase of 75% from the average daily volume of 498,498 shares. The stock had previously closed at $3.51.
Analyst Ratings Changes
Several equities research analysts recently weighed in on IVA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Tuesday, April 21st. Truist Financial began coverage on shares of Inventiva in a report on Thursday, March 19th. They set a “buy” rating and a $13.00 price objective on the stock. Finally, Wall Street Zen downgraded shares of Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $16.56.
View Our Latest Stock Report on IVA
Inventiva Trading Down 6.7%
Inventiva (NASDAQ:IVA – Get Free Report) last posted its quarterly earnings results on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The firm had revenue of $0.01 million during the quarter. As a group, sell-side analysts forecast that Inventiva S.A. Sponsored ADR will post -0.79 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in IVA. Creative Planning purchased a new stake in shares of Inventiva in the second quarter worth about $32,000. Commonwealth Equity Services LLC grew its position in shares of Inventiva by 19.6% during the 4th quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after purchasing an additional 12,704 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Inventiva in the fourth quarter worth $60,000. XTX Topco Ltd bought a new stake in Inventiva during the fourth quarter valued at $84,000. Finally, NewEdge Advisors LLC purchased a new position in Inventiva during the third quarter worth about $116,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.
About Inventiva
Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.
The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.
Read More
- Five stocks we like better than Inventiva
- Energy Fuels Just Made a Bold Bet on Rare Earth Magnets
- Washington’s Quantum Push Puts IBM and IonQ on the Throne
- FedEx’s Earnings Drop May Be Missing the Bigger Freight Story
- Why KB Home Could Reward Patient Investors Later
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
